메뉴 건너뛰기




Volumn 27, Issue 3, 2015, Pages 276-281

B-type proto-oncogene-mutated tumors of colon cancer: Promising therapeutic approaches

Author keywords

B type proto oncogene inhibitor; colorectal cancer; combined therapy

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ALPELISIB; B RAF KINASE; B RAF KINASE INHIBITOR; BEVACIZUMAB; BINIMETINIB; CAPECITABINE; CEP 32496; CETUXIMAB; CHIR 265; DABRAFENIB; ENCORAFENIB; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PANITUMUMAB; PLX 3603; SELUMETINIB; SORAFENIB; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; XL 281; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; SULFONAMIDE;

EID: 84928503445     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000184     Document Type: Review
Times cited : (2)

References (38)
  • 1
    • 84897012482 scopus 로고    scopus 로고
    • BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: A systematic review and meta-analysis
    • Chen D, Huang JF, Liu K, et al. BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One 2014; 9:e90607.
    • (2014) PLoS One , vol.9 , pp. e90607
    • Chen, D.1    Huang, J.F.2    Liu, K.3
  • 2
    • 84904736732 scopus 로고    scopus 로고
    • BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer
    • Yaeger R, Cercek A, Chou JF, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer 2014; 120:2316-2324.
    • (2014) Cancer , vol.120 , pp. 2316-2324
    • Yaeger, R.1    Cercek, A.2    Chou, J.F.3
  • 3
    • 84919466731 scopus 로고    scopus 로고
    • The BRAF mutation is associated with the prognosis in colorectal cancer
    • Ahn TS, Jeong D, Son MW, et al. The BRAF mutation is associated with the prognosis in colorectal cancer. J Cancer Res Clin Oncol 2014; 140:1863-1871.
    • (2014) J Cancer Res Clin Oncol , vol.140 , pp. 1863-1871
    • Ahn, T.S.1    Jeong, D.2    Son, M.W.3
  • 4
    • 84878581633 scopus 로고    scopus 로고
    • KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells
    • Lewandowska MA, Jozwicki W, Zurawski B. KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells. Mol Diagn Ther 2013; 17:193-203.
    • (2013) Mol Diagn Ther , vol.17 , pp. 193-203
    • Lewandowska, M.A.1    Jozwicki, W.2    Zurawski, B.3
  • 5
    • 84999986042 scopus 로고    scopus 로고
    • The MAPK pathway across different malignancies: A new perspective
    • Burotto M, Chiou VL, Lee JM, Kohn EC. The MAPK pathway across different malignancies: a new perspective. Cancer 2014; 120:3446-3456.
    • (2014) Cancer , vol.120 , pp. 3446-3456
    • Burotto, M.1    Chiou, V.L.2    Lee, J.M.3    Kohn, E.C.4
  • 6
    • 84898005888 scopus 로고    scopus 로고
    • ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer
    • Ye Q, Cai W, Zheng Y, et al. ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene 2014; 33:1828-1839.
    • (2014) Oncogene , vol.33 , pp. 1828-1839
    • Ye, Q.1    Cai, W.2    Zheng, Y.3
  • 7
    • 63149194964 scopus 로고    scopus 로고
    • (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
    • Pratilas CA, Taylor BS, Ye Q, et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA 2009; 106:4519-4524.
    • (2009) Proc Natl Acad Sci USA , vol.106 , pp. 4519-4524
    • Pratilas, C.A.1    Taylor, B.S.2    Ye, Q.3
  • 8
    • 84898462986 scopus 로고    scopus 로고
    • Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer
    • Roper J, Sinnamon MJ, Coffee EM, et al. Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer. Cancer Lett 2014; 347:204-211.
    • (2014) Cancer Lett , vol.347 , pp. 204-211
    • Roper, J.1    Sinnamon, M.J.2    Coffee, E.M.3
  • 9
    • 84874762857 scopus 로고    scopus 로고
    • Molecular biological diagnostics of KRAS and BRAF mutations in patients with colorectal cancer - Laboratory experience
    • Robesova B, Bajerova M, Vasikova A, et al. Molecular biological diagnostics of KRAS and BRAF mutations in patients with colorectal cancer - laboratory experience. Klin Onkol 2013; 26:25-30.
    • (2013) Klin Onkol , vol.26 , pp. 25-30
    • Robesova, B.1    Bajerova, M.2    Vasikova, A.3
  • 10
    • 84898901842 scopus 로고    scopus 로고
    • Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer
    • Kim B, Park SJ, Cheon JH, et al. Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer. World J Gastroenterol 2014; 20:4370-4376.
    • (2014) World J Gastroenterol , vol.20 , pp. 4370-4376
    • Kim, B.1    Park, S.J.2    Cheon, J.H.3
  • 11
    • 84888883391 scopus 로고    scopus 로고
    • Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer
    • Marchoudi N, Amrani Hassani Joutei H, Jouali F, et al. Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. Pathol Biol (Paris) 2013; 61:273-276.
    • (2013) Pathol Biol (Paris) , vol.61 , pp. 273-276
    • Marchoudi, N.1    Amrani Hassani Joutei, H.2    Jouali, F.3
  • 12
    • 84908292763 scopus 로고    scopus 로고
    • FDA approval summary: Vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation
    • Kim G, McKee AE, Ning YM, et al. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Clin Cancer Res 2014; 20:4994-5000.
    • (2014) Clin Cancer Res , vol.20 , pp. 4994-5000
    • Kim, G.1    McKee, A.E.2    Ning, Y.M.3
  • 13
    • 84883237132 scopus 로고    scopus 로고
    • Dabrafenib: First global approval
    • Ballantyne AD, Garnock-Jones KP. Dabrafenib: first global approval. Drugs 2013; 73:1367-1376.
    • (2013) Drugs , vol.73 , pp. 1367-1376
    • Ballantyne, A.D.1    Garnock-Jones, K.P.2
  • 14
    • 84880780573 scopus 로고    scopus 로고
    • Trametinib: First global approval
    • Wright CJ, McCormack PL. Trametinib: first global approval. Drugs 2013; 73:1245-1254.
    • (2013) Drugs , vol.73 , pp. 1245-1254
    • Wright, C.J.1    McCormack, P.L.2
  • 15
    • 84903201668 scopus 로고    scopus 로고
    • BRAF mutations: Signaling, epidemiology, and clinical experience in multiple malignancies
    • Hall RD, Kudchadkar RR. BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies. Cancer Contr 2014; 21:221-230.
    • (2014) Cancer Contr , vol.21 , pp. 221-230
    • Hall, R.D.1    Kudchadkar, R.R.2
  • 16
    • 84896721004 scopus 로고    scopus 로고
    • EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: A prospective follow-up study
    • Schweiger T, Hegedus B, Nikolowsky C, et al. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study. Ann Surg Oncol 2014; 21:946-954.
    • (2014) Ann Surg Oncol , vol.21 , pp. 946-954
    • Schweiger, T.1    Hegedus, B.2    Nikolowsky, C.3
  • 17
    • 84889962719 scopus 로고    scopus 로고
    • The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
    • Huang CW, Tsai HL, Chen YT, et al. The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. BMC Cancer 2013; 13:599.
    • (2013) BMC Cancer , vol.13 , pp. 599
    • Huang, C.W.1    Tsai, H.L.2    Chen, Y.T.3
  • 18
    • 84896044667 scopus 로고    scopus 로고
    • Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: A meta-analysis of randomized studies
    • Cui D, Cao D, Yang Y, et al. Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies. Mol Biol Rep 2014; 41:1291-1298.
    • (2014) Mol Biol Rep , vol.41 , pp. 1291-1298
    • Cui, D.1    Cao, D.2    Yang, Y.3
  • 19
    • 84896689696 scopus 로고    scopus 로고
    • KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells
    • Nakadate Y, Kodera Y, Kitamura Y, et al. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells. Int J Cancer 2014; 134:2146-2155.
    • (2014) Int J Cancer , vol.134 , pp. 2146-2155
    • Nakadate, Y.1    Kodera, Y.2    Kitamura, Y.3
  • 20
    • 84919662543 scopus 로고    scopus 로고
    • BRAF V600E mutation as a predictive factor of anti-EGFR monoclonal antibodies therapeutic effects in metastatic colorectal cancer: A meta-analysis
    • Wang Q, Hu WG, Song QB, Wei J. BRAF V600E mutation as a predictive factor of anti-EGFR monoclonal antibodies therapeutic effects in metastatic colorectal cancer: a meta-analysis. Chi Med Sci J 2014; 29:197-203.
    • (2014) Chi Med Sci J , vol.29 , pp. 197-203
    • Wang, Q.1    Hu, W.G.2    Song, Q.B.3    Wei, J.4
  • 21
    • 84929141867 scopus 로고    scopus 로고
    • Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials
    • Sorich MJ, Wiese MD, Rowland A, et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol ESMO 2015; 26:13-21.
    • (2015) Ann Oncol ESMO , vol.26 , pp. 13-21
    • Sorich, M.J.1    Wiese, M.D.2    Rowland, A.3
  • 22
    • 84928487327 scopus 로고    scopus 로고
    • KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: A meta-analysis
    • Li W, Shi Q, Wang W, et al. KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis. Colorectal Dis 2014; 16:O370-O378.
    • (2014) Colorectal Dis , vol.16 , pp. O370-O378
    • Li, W.1    Shi, Q.2    Wang, W.3
  • 23
    • 77956030786 scopus 로고    scopus 로고
    • Inhibition of mutated, activated BRAF in metastatic melanoma
    • Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. NEJM 2010; 363:809-819.
    • (2010) NEJM , vol.363 , pp. 809-819
    • Flaherty, K.T.1    Puzanov, I.2    Kim, K.B.3
  • 24
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. NEJM 2011; 364:2507-2516.
    • (2011) NEJM , vol.364 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 25
    • 78649723255 scopus 로고    scopus 로고
    • PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors
    • Chicago, IL; 2010
    • Kopetz S Desai J, Chan E, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. ASCO AnnualMeeting 2010; Chicago, IL; 2010.
    • (2010) ASCO AnnualMeeting
    • Kopetz Desai S, J.1    Chan, E.2
  • 26
    • 84901631862 scopus 로고    scopus 로고
    • Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAFmutant colorectal cancer cells
    • Hirschi B, Gallmeier E, Ziesch A, et al. Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAFmutant colorectal cancer cells. Mol Cancer 2014; 13:122.
    • (2014) Mol Cancer , vol.13 , pp. 122
    • Hirschi, B.1    Gallmeier, E.2    Ziesch, A.3
  • 27
    • 84873360893 scopus 로고    scopus 로고
    • Resistance to BRAF inhibition in BRAFmutant colon cancer can be overcome with PI3K inhibition or demethylating agents
    • Mao M, Tian F, Mariadason JM, et al. Resistance to BRAF inhibition in BRAFmutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2013; 19:657-667.
    • (2013) Clin Cancer Res , vol.19 , pp. 657-667
    • Mao, M.1    Tian, F.2    Mariadason, J.M.3
  • 28
    • 84878066430 scopus 로고    scopus 로고
    • Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer
    • Coffee EM, Faber AC, Roper J, et al. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. Clin Cancer Res 2013; 19:2688-2698.
    • (2013) Clin Cancer Res , vol.19 , pp. 2688-2698
    • Coffee, E.M.1    Faber, A.C.2    Roper, J.3
  • 29
    • 84863230465 scopus 로고    scopus 로고
    • Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
    • Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483:100-103.
    • (2012) Nature , vol.483 , pp. 100-103
    • Prahallad, A.1    Sun, C.2    Huang, S.3
  • 30
    • 84861863158 scopus 로고    scopus 로고
    • EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
    • Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2:227-235.
    • (2012) Cancer Discov , vol.2 , pp. 227-235
    • Corcoran, R.B.1    Ebi, H.2    Turke, A.B.3
  • 31
    • 84881223991 scopus 로고    scopus 로고
    • Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer
    • Spreafico A, Tentler JJ, Pitts TM, et al. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clin Cancer Res 2013; 19:4149-4162.
    • (2013) Clin Cancer Res , vol.19 , pp. 4149-4162
    • Spreafico, A.1    Tentler, J.J.2    Pitts, T.M.3
  • 32
    • 84897407253 scopus 로고    scopus 로고
    • Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib
    • Cheng H, Chang Y, Zhang L, et al. Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib. J Med Chem 2014; 57:2692-2703.
    • (2014) J Med Chem , vol.57 , pp. 2692-2703
    • Cheng, H.1    Chang, Y.2    Zhang, L.3
  • 33
    • 84863012433 scopus 로고    scopus 로고
    • Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer
    • Yang H, Higgins B, Kolinsky K, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 2012; 72:779-789.
    • (2012) Cancer Res , vol.72 , pp. 779-789
    • Yang, H.1    Higgins, B.2    Kolinsky, K.3
  • 34
    • 79952001479 scopus 로고    scopus 로고
    • Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer
    • Galal KM, Khaled Z, Mourad AM. Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer. Indian J Cancer 2011; 48:47-54.
    • (2011) Indian J Cancer , vol.48 , pp. 47-54
    • Galal, K.M.1    Khaled, Z.2    Mourad, A.M.3
  • 35
    • 84892402986 scopus 로고    scopus 로고
    • Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma
    • Connolly K, Brungs D, Szeto E, Epstein RJ. Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma. Curr Oncol 2014; 21:e151-e154.
    • (2014) Curr Oncol , vol.21 , pp. e151-e154
    • Connolly, K.1    Brungs, D.2    Szeto, E.3    Epstein, R.J.4
  • 36
    • 84903828105 scopus 로고    scopus 로고
    • Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: A case report
    • Capalbo C, Marchetti P, Coppa A, et al. Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report. Cancer Biol Ther 2014; 15:826-831.
    • (2014) Cancer Biol Ther , vol.15 , pp. 826-831
    • Capalbo, C.1    Marchetti, P.2    Coppa, A.3
  • 37
    • 84880100858 scopus 로고    scopus 로고
    • Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer
    • Al-Marrawi MY, Saroya BS, Brennan MC, et al. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biol Ther 2013; 14:703-710.
    • (2013) Cancer Biol Ther , vol.14 , pp. 703-710
    • Al-Marrawi, M.Y.1    Saroya, B.S.2    Brennan, M.C.3
  • 38
    • 78651418282 scopus 로고    scopus 로고
    • Mutant BRAF melanomas: Dependence and resistance
    • Poulikakos PI, Rosen N. Mutant BRAF melanomas: dependence and resistance. Cancer Cell 2011; 19:11-15.
    • (2011) Cancer Cell , vol.19 , pp. 11-15
    • Poulikakos, P.I.1    Rosen, N.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.